Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma

Previous studies noted discordance of programmed death‐1 (PD‐1) and one of its ligands (PD‐L1) across patient‐matched primary and metastatic clear cell renal cell carcinoma (ccRCC). There are inconsistencies if the primary or metastatic tumor has higher expression, and whether metastatic tumor expression is associated with patient outcome. Thus, we examined PD‐1 and PD‐L1 in patient‐matched tumors using a large number of ccRCC patients with long follow‐up.

[1]  H. Zeng,et al.  Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma , 2019, BMC Cancer.

[2]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[3]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[4]  R. Montironi,et al.  The Identification of Immunological Biomarkers in Kidney Cancers , 2018, Front. Oncol..

[5]  S. Signoretti,et al.  Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robert J. Jones,et al.  Immune checkpoint inhibitors in renal cell carcinoma , 2017, Clinical science.

[7]  M. Atkins,et al.  Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  T. Ho,et al.  PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation , 2015, Cancer Immunology Research.

[9]  D. McDermott,et al.  Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma , 2015, Therapeutic advances in urology.

[10]  G. Freeman,et al.  Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.

[11]  A. Ghazalpour,et al.  Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[12]  Y. Kluger,et al.  PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases , 2014, Journal of Cancer.

[13]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[14]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[15]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.